Skip to main content
Fig. 2 | Annals of Clinical Microbiology and Antimicrobials

Fig. 2

From: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Fig. 2

Potential carbapenem days spared.  DOT days of therapy. *Due to resistance, site of infection or contraindications. Individual bars represent the DOT per 100 patient-days of antimicrobial therapy and percentage of potential carbapenem days spared for each agent divided into setting of administration and empiric vs definitive therapy

Back to article page